Protalix BioTherapeutics (PLX) Shares Outstanding (Weighted Average) (2010 - 2026)

Protalix BioTherapeutics' Shares Outstanding (Weighted Average) history runs 17 years deep, the most recent figure standing at $79.8 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 4.23% year-over-year to $79.8 million; the TTM figure through Mar 2026 stood at $79.8 million (up 4.23% YoY), while the FY2025 annual figure was $78.5 million, up 8.29% from the prior year.
• Shares Outstanding (Weighted Average) was $79.8 million for Q1 2026 at Protalix BioTherapeutics, up from $78.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $79.8 million in Q1 2026 to a low of $45.8 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $66.3 million across 5 years, with a median of $72.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) climbed 4.16% in 2022, then surged 39.28% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $48.5 million in 2022, then soared by 39.28% to $67.5 million in 2023, then grew by 7.43% to $72.5 million in 2024, then rose by 8.29% to $78.5 million in 2025, then grew by 1.66% to $79.8 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $79.8 million (Q1 2026), $78.5 million (Q4 2025), and $78.2 million (Q3 2025), per Business Quant data.